瑞戈非尼-话题@MedSci

#瑞戈非尼#

2篇内容 | 2073人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2251999, encodeId=188722519995e, content=<a href='/topic/show?id=7efe68e26bd' target=_blank style='color:#2F92EE;'>#瑞戈非尼#</a> <a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a> <a href='/topic/show?id=844712422e13' target=_blank style='color:#2F92EE;'>#微卫星稳定转移性结直肠癌#</a>, objectTitle=Nat.Commun：瑞戈非尼联合信迪利单抗作为微卫星稳定转移性结直肠癌的挽救治疗方案：一项单臂、开放标签、Ⅱ期临床试验, objectType=article, longId=863196, objectId=5e6b863196ce, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250213/1739456841958_6145188.jpg, objectUrl=/article/show_article.do?id=5e6b863196ce, replyNumber=0, likeNumber=15, createdTime=2025-02-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=5e6b863196ce, moduleTitle=Nat.Commun：瑞戈非尼联合信迪利单抗作为微卫星稳定转移性结直肠癌的挽救治疗方案：一项单臂、开放标签、Ⅱ期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e6b863196ce)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200602, encodeId=c0f422006027f, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a> <a href='/topic/show?id=7efe68e26bd' target=_blank style='color:#2F92EE;'>#瑞戈非尼#</a> <a href='/topic/show?id=7bba10e99631' target=_blank style='color:#2F92EE;'>#微卫星稳定#</a>, objectTitle=哪些MSS难治转移性结直肠癌首选瑞戈非尼+免疫治疗？HER2/HER3基因筛查有意义, objectType=article, longId=823434, objectId=3be38234343b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/prescription-form-with-medical-stethoscope-9ZRKVHM.jpg, objectUrl=/article/show_article.do?id=3be38234343b, replyNumber=0, likeNumber=139, createdTime=2024-04-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3be38234343b, moduleTitle=哪些MSS难治转移性结直肠癌首选瑞戈非尼+免疫治疗？HER2/HER3基因筛查有意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3be38234343b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2195712, encodeId=e1e22195e1263, content=<a href='/topic/show?id=7efe68e26bd' target=_blank style='color:#2F92EE;'>#瑞戈非尼#</a> <a href='/topic/show?id=940f11210e24' target=_blank style='color:#2F92EE;'>#纳武利尤#</a> <a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a> <a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, objectTitle=读书报告 | 瑞戈非尼联合纳武利尤和化疗治疗美国食管癌和胃癌的II期临床研究, objectType=article, longId=818038, objectId=911c818038da, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/black-surgeon-giving-instruction-to-medical-team-TMPFGNZ.jpg, objectUrl=/article/show_article.do?id=911c818038da, replyNumber=0, likeNumber=96, createdTime=2024-03-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=911c818038da, moduleTitle=读书报告 | 瑞戈非尼联合纳武利尤和化疗治疗美国食管癌和胃癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=911c818038da)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188862, encodeId=7942218886238, content=<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝细胞癌#</a> <a href='/topic/show?id=7efe68e26bd' target=_blank style='color:#2F92EE;'>#瑞戈非尼#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a>, objectTitle=Nat. Med | 瑞戈非尼联合纳武利尤单抗治疗不可切除的肝细胞癌：2期RENOBATE试验, objectType=article, longId=814338, objectId=857d814338cc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240223/1708618074433_6145188.jpg, objectUrl=/article/show_article.do?id=857d814338cc, replyNumber=0, likeNumber=0, createdTime=2024-02-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=857d814338cc, moduleTitle=Nat. Med | 瑞戈非尼联合纳武利尤单抗治疗不可切除的肝细胞癌：2期RENOBATE试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=857d814338cc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184110, encodeId=e4922184110de, content=<a href='/topic/show?id=18d293422fd' target=_blank style='color:#2F92EE;'>#转移性结直肠癌#</a> <a href='/topic/show?id=7efe68e26bd' target=_blank style='color:#2F92EE;'>#瑞戈非尼#</a> <a href='/topic/show?id=b64e106e80cc' target=_blank style='color:#2F92EE;'>#索托拉西布#</a> <a href='/topic/show?id=6ab311052253' target=_blank style='color:#2F92EE;'>#2024 ASCO GI#</a> <a href='/topic/show?id=ef4b11056996' target=_blank style='color:#2F92EE;'>#三氟尿苷/替吡嘧啶#</a>, objectTitle=ASCO GI 2024：转移性结直肠癌 (mCRC) 患者接受索托拉西布和帕尼单抗与三氟尿苷/替吡嘧啶或瑞戈非尼治疗后的生活质量评估（CodeBreaK 300研究）, objectType=article, longId=811122, objectId=563c81112210, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240122/1705890201768_8624274.png, objectUrl=/article/show_article.do?id=563c81112210, replyNumber=0, likeNumber=114, createdTime=2024-01-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=563c81112210, moduleTitle=ASCO GI 2024：转移性结直肠癌 (mCRC) 患者接受索托拉西布和帕尼单抗与三氟尿苷/替吡嘧啶或瑞戈非尼治疗后的生活质量评估（CodeBreaK 300研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=563c81112210)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177961, encodeId=ad2121e796145, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a> <a href='/topic/show?id=7efe68e26bd' target=_blank style='color:#2F92EE;'>#瑞戈非尼#</a>, objectTitle=肿瘤免疫治疗大咖谈 | 结直肠癌肝转移治疗策略优化, objectType=article, longId=807314, objectId=906c80e31455, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PX4RLTJ.jpg, objectUrl=/article/show_article.do?id=906c80e31455, replyNumber=0, likeNumber=114, createdTime=2023-12-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=906c80e31455, moduleTitle=肿瘤免疫治疗大咖谈 | 结直肠癌肝转移治疗策略优化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=906c80e31455)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2117673, encodeId=7817211e673c3, content=<a href='/topic/show?id=7efe68e26bd' target=_blank style='color:#2F92EE;'>#瑞戈非尼#</a>用于既往治疗过的<a href='/topic/show?id=18d293422fd' target=_blank style='color:#2F92EE;'>#转移性结直肠癌#</a><a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>, objectTitle=2023 NICE 技术鉴定指导意见：瑞戈非尼用于既往治疗过的转移性结直肠癌[TA866], objectType=guider, longId=22282, objectId=b94ac1c00296a3b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=b94ac1c00296a3b8, replyNumber=0, likeNumber=142, createdTime=2023-03-05, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b94ac1c00296a3b8, moduleTitle=2023 NICE 技术鉴定指导意见：瑞戈非尼用于既往治疗过的转移性结直肠癌[TA866], moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=b94ac1c00296a3b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1220490, encodeId=c04f1220490e2, content=<a href='/topic/show?id=7efe68e26bd' target=_blank style='color:#2F92EE;'>#瑞戈非尼#</a>联合<a href='/topic/show?id=4e9ae7349f2' target=_blank style='color:#2F92EE;'>#纳武单抗#</a>治疗<a href='/topic/show?id=18d293422fd' target=_blank style='color:#2F92EE;'>#转移性结直肠癌#</a><a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>, objectTitle=Eur J Cancer：瑞戈非尼联合纳武单抗治疗转移性结直肠癌, objectType=article, longId=727120, objectId=36ade27120a4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220516/1652695606423_2110107.JPG, objectUrl=/article/show_article.do?id=36ade27120a4, replyNumber=0, likeNumber=187, createdTime=2022-05-17, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ade27120a4, moduleTitle=Eur J Cancer：瑞戈非尼联合纳武单抗治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36ade27120a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

瑞戈非尼

2020-05-29

梅斯管理员

#瑞戈非尼# #信迪利单抗# #微卫星稳定转移性结直肠癌#

Nat.Commun：瑞戈非尼联合信迪利单抗作为微卫星稳定转移性结直肠癌的挽救治疗方案：一项单臂、开放标签、Ⅱ期临床试验

2025-02-15发表于威斯康星

梅斯管理员

#结直肠癌# #免疫治疗# #瑞戈非尼# #微卫星稳定#

哪些MSS难治转移性结直肠癌首选瑞戈非尼+免疫治疗？HER2/HER3基因筛查有意义

2024-04-26发表于上海

梅斯管理员

#瑞戈非尼# #纳武利尤# #食管癌# #胃癌#

读书报告 | 瑞戈非尼联合纳武利尤和化疗治疗美国食管癌和胃癌的II期临床研究

2024-03-27发表于陕西省

梅斯管理员

#肝细胞癌# #瑞戈非尼# #纳武利尤单抗#

Nat. Med | 瑞戈非尼联合纳武利尤单抗治疗不可切除的肝细胞癌：2期RENOBATE试验

2024-02-23发表于上海

梅斯管理员

#转移性结直肠癌# #瑞戈非尼# #索托拉西布# #2024 ASCO GI# #三氟尿苷/替吡嘧啶#

ASCO GI 2024：转移性结直肠癌 (mCRC) 患者接受索托拉西布和帕尼单抗与三氟尿苷/替吡嘧啶或瑞戈非尼治疗后的生活质量评估（CodeBreaK 300研究）

2024-01-26发表于上海

梅斯管理员

#结直肠癌# #肝转移# #瑞戈非尼#

肿瘤免疫治疗大咖谈 | 结直肠癌肝转移治疗策略优化

2023-12-29发表于上海

lifestar

#瑞戈非尼#用于既往治疗过的#转移性结直肠癌##结直肠癌#

2023 NICE 技术鉴定指导意见：瑞戈非尼用于既往治疗过的转移性结直肠癌[TA866]

2023-03-05发表于上海

赛华佗

#瑞戈非尼#联合#纳武单抗#治疗#转移性结直肠癌##结直肠癌#

Eur J Cancer：瑞戈非尼联合纳武单抗治疗转移性结直肠癌

2022-05-17